Bookmark
Forward
QuickView for Phendimetrazine (compound)
PubChem
| Name: | phendimetrazine |
|---|---|
| PubChem Compound ID: | 111021 |
| Molecular formula: | C12H18ClNO |
| Molecular weight: | 227.73 g/mol |
| Synonyms: |
21784-30-5; 17140-98-6; Morpholine, 3,4-dimethyl-2-phenyl-, hydrochloride, (+-)-; (+-)-3,4-Dimethyl-2-phenylmorpholine hydrochloride; 4607-46-9
|
DrugBank
Identification
| Name: | phendimetrazine |
|---|---|
| Name (isomeric): | DB01579 |
| Drug Type: | small molecule |
| Synonyms: |
(+)-phendimetrazine; (2S,3S)-3,4-Dimethyl-2-phenylmorpholine; d-2-Phenyl-3,4-dimethylmorpholine; 3,4-Dimethyl-2-phenylmorpholine; 3-Phenyl-2-methylmorpholine; (+)-3,4-Dimethyl-2-phenylmorpholine
|
| Brand: | X-trozine, Sedafamen, Prelu-2, Mephenmetrazine, Antapentan, Bacarate, Adphen, Hyrex, Bontril, Dyrexan, Wehless |
| Category: | Anorexigenic Agents |
| CAS number: | 634-03-7 |
Pharmacology
| Indication: | Used in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. |
|---|---|
| Pharmacology: |
Phendimetrazine is a phenylalkylamine sympathomimetic amine with pharmacological activity similar to the prototype drugs of this class used in obesity, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance has been demonstrated with all drugs of this class in which these ph...
show more » |
| Mechanism of Action: | Phendimetrazine may act in a similar way to amphetamines in that it activates the alpha-adrenergic system to induce an appetite suppressive and metabolic increase effect. The drug also acts as a norepinephrine-dopamine releasing agent (NDRA). It can bind to and reverse the NET. |
| Absorption: | Peak plasma levels occur within 1 to 3 hours. Absorption is usually complete by 4 to 6 hours. |
| Biotransformation: | Approximately 30% of a given dose of phendimetrazine is metabolized into phenmetrazine, which may account for part of its anorectic effect, and probably also influences abuse potential; individuals who metabolise a greater proportion of phendimetrazine into phenmetrazine are more likely to develop problems with dependence and addiction |
| Route of elimination: | The major route of elimination is via the kidneys where most of the drug and metabolites are excreted. |
| Half Life: | 19-24 hours |
| Toxicity: | Acute overdosage of phendimetrazine may manifest itself by the following signs and symptoms: unusual restlessness, confusion, belligerance, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmias, hypertension, or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Poisoning may result in convulsions, coma and death. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
